



ASX ANNOUNCEMENT

12 December 2018

CardieX Executes Development Agreement with Silicon Valley-based Blumio to Commence Rapid Development of Cutting-Edge Intelligent Sensor Technology for Blood Pressure Wearable Devices.

Highlights:

- Execution of Co-Development Agreement (the “Agreement”) with Blumio to jointly develop intelligent sensor technology that can be integrated into wearable devices, such as fitness trackers, smartwatches, and medical devices.
- CardieX to provide key algorithms and FDA-approved technology for measuring central arterial blood pressure. Blumio to provide blood pressure sensor technology.
- Co-developed wearable device to measure both brachial and central blood pressure and assess arterial stiffness and general cardiovascular health.
- Cuffless wearable blood pressure monitoring recently identified by CNBC as a US\$45B market opportunity.
- Combination of CardieX IP together with Blumio’s sensor has potential to significantly disrupt fast-growing health wearables market - including the diagnosis and treatment of hypertension and related cardiovascular disorders.
- Both parties to share equal 50/50 ownership and rights in the final developed product under the Agreement.
- Recent trials and studies on Blumio’s technology and CardieX IP have given the parties confidence to jointly move to the next stage of development towards commercialization as detailed under the Agreement.
- On completion of deliverables under the Agreement, CardieX will also be granted an additional 2.5% converting equitable interest in Blumio, taking CardieX’s ownership in Blumio on conversion to 10%.

CardieX Limited (ASX: CDX, the Company) is pleased to announce that it has expanded on its previously reported Collaboration and Development Agreement (the “CDA”) with Blumio, Inc. and is now rapidly moving forward to develop a jointly (50/50) owned intelligent sensor technology that can be integrated into a wide range of consumer and medical wearable devices.

CardieX had previously announced the CDA with Blumio under which the companies agreed to collaborate on the development of sensor based blood pressure technology. This new Agreement

For personal use only



expands on the CDA by detailing the joint responsibilities and ownership of the technology as well as the joint equal ownership interest in the final product output.

Under the terms of this new Agreement, the companies will jointly develop ground-breaking sensor technology which will be able to read both brachial and central blood pressures and assess arterial stiffness and cardiovascular health. The wearable sensor technology combines CardieX's Sphygmocor® IP with Blumio's blood pressure sensor technology in a form that can be licensed across a broad segment of consumer and medical applications as well as smartwatch integrations.

Under the terms of the Agreement the parties have agreed to cross-licence their respective IP on a non-exclusive basis for the express purpose of developing this joint technology. The companies have also agreed to split ownership of and will hold equal 50/50 commercial rights to the joint technology as well as associated copyrights and patents.

CardieX and Blumio will also create a new brand identity under which this technology can be marketed. The collaboration will directly launch CardieX into the direct-to-consumer health and wellness market, as it is anticipated that this innovative sensor technology will also lead to lucrative licensing partnerships with key wearable device, digital health, and software companies.

CardieX recently reported encouraging results of an 8-week trial with Blumio and The Faculty of Medicine & Health Sciences at Macquarie University to validate the commercial application of the Company's pulse wave analysis (PWA) technology in a wearable blood pressure sensor.

The results of the trial showed that Blumio's sensor returns a high degree of cardiovascular blood pressure data as measured by CardieX's technology. The trial also gave a strong indication that further central blood pressure (cBP) readings can be extracted from the Blumio sensor in a wearable device using CardieX's proprietary machine learning algorithms.

Blumio has also initiated a further large-scale clinical trial at the US-based Deborah Heart and Lung Center to demonstrate the accuracy of the company's non-invasive wearable blood pressure sensor.

The non-randomised study with 200 participants compares the signal from the Blumio sensor with signals from the current standard in blood pressure monitoring in hospitals, the invasive arterial line, as well as to automated blood pressure cuffs. The study commenced 30 October 2018 and, together with the Macquarie University trial, has now given the parties confidence to move forward on a jointly developed product under the Agreement.

CardieX CEO, Craig Cooper commented, "This is a key milestone in the company's strategic plan and strongly positions CardieX in the US\$45B market for sensor-based wearable cardiovascular monitoring devices as we move towards product development. Our cutting-edge blood pressure analytics technology is second to none and I firmly believe that ultimately our IP, together with the Blumio sensor, will globally disrupt how we diagnose and manage hypertension and heart disorders."

For personal use only



For more information please contact:

Chief Executive Officer

Craig Cooper

Ph: +61 429 993 399

ccooper@cardiex.com

Investor Relations

Peter Taylor

Ph: +61 412 036 231

peter@nwrcommunications.com.au

About CardieX

CardieX is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders.

CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.

About Blumio

Blumio Inc is a Silicon Valley based company that develops non-invasive radio frequency sensors designed to measure blood pressure and other cardiovascular diagnostics. The company is backed by leading Silicon Valley investors including the Thiel Foundation.

For personal use only